Lianshan Guo

Lianshan Guo

Auto-generated profile, based on publicly available information

Lianshan Guo

Department of Emergency, The First People's Hospital of Foshan (Foshan Hospital Affiliated to Southern University of Science and Technology), School of Medicine, Southern University of Science and Technology, Foshan, Guangdong, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2024 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
GAGuanghui An
Guanghui An
HZHeming Zheng
Heming Zheng
LGLianshan Guo
Lianshan Guo
JHJingmei Huang
Jingmei Huang
CYCongling Yang
Congling Yang
YZYanqiu Zhu
Yanqiu Zhu

8 December 2023 in Chemical Engineering Journal
Verified
Journal Article
Closed access
ZBZhihao Bai
Zhihao Bai
LGLianShan Guo
LianShan Guo
JHJianFeng Huang
JianFeng Huang
HLHaoYu Li
HaoYu Li
GAGuanghui An
Guanghui An
YZYanqiu Zhu
Yanqiu Zhu

1 May 2024 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
EHEnhao Huang
Enhao Huang
HLHuadao Li
Huadao Li
HHHanghang Han
Hanghang Han
LGLianshan Guo
Lianshan Guo
YLYubing Liang
Yubing Liang
XDXueke Du
Xueke Du
Purpose: The primary objective of this study was to develop an innovative nanomedicine-based therapeutic strategy to alleviate Postoperative Neurocognitive Disorder (PND) in patients undergoing surgery. Patients and Methods: To achieve this goal, polydopamine-coated Kaempferol-loaded Metal-Organic Framework nanoparticles (pDA/KAE@ZIF-8) were synthesized and evaluated. The study involved encapsulating Kaempferol (KAE) within ZIF-8 nanoparticles, followed by coating with polydopamine (PDA) to enhance biocompatibility and targeted delivery. The characterization of these nanoparticles (NPs) was conducted using various techniques including Scanning Electron Microscopy, Fourier-Transform Infrared Spectroscopy, X-ray Diffraction, and Ultraviolet-Visible spectroscopy. The efficacy of pDA/KAE@ZIF-8 NPs was tested in both in vitro and in vivo models, specifically focusing on their ability to penetrate the blood-brain barrier and protect neuronal cells against oxidative stress. Results: The study found that pDA/KAE@ZIF-8 NPs efficiently penetrated the blood-brain barrier and were significantly taken up by neuronal cells. These nanoparticles demonstrated remarkable Reactive Oxygen Species (ROS) scavenging capabilities and stability under physiological conditions. In vitro studies showed that pDA/KAE@ZIF-8 NPs provided protection to HT-22 neuronal cells against H2O2-induced oxidative stress, reduced the levels of pro-inflammatory cytokines, and decreased apoptosis rates. In a PND mouse model, the treatment with pDA/KAE@ZIF-8 NPs significantly improved cognitive functions, surpassing the effects of KAE alone. This improvement was substantiated through behavioral tests and a noted reduction in hippocampal inflammation. Conclusion: The findings from this study underscore the potential of pDA/KAE@ZIF-8 NPs as an effective nanotherapeutic agent for PND. This approach offers a novel direction in the postoperative care of elderly patients, with the potential to transform the therapeutic landscape for neurocognitive disorders following surgery. The application of nanotechnology in this context opens new avenues for more effective and targeted treatments, thereby improving the quality of life for patients suffering from PND.

1 February 2024 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
TLTing Li
Ting Li
LGLianshan Guo
Lianshan Guo
JLJiaxu Li
Jiaxu Li
XMXingyu Mu
Xingyu Mu
LLLijuan Liu
Lijuan Liu
GJGuan Qiao Jin
Guan Qiao Jin
Background: The anti-Programmed Death-Ligand 1 (termed aPD-L1) immune checkpoint blockade therapy has emerged as a promising treatment approach for various advanced solid tumors. However, the effect of aPD-L1 inhibitors limited by the tumor microenvironment makes most patients exhibit immunotherapy resistance. Methods: We conjugated the Sialyl Lewis X with a polyethylene glycol-coated ultrasmall superparamagnetic iron oxide (USPIO-PEG) to form UPS nanoparticles (USPIO-PEG-SLex, termed UPS). The physicochemical properties of UPS were tested and characterized. Transmission electron microscopy and ICP-OES were used to observe the cellular uptake and targeting ability of UPS. Flow cytometry, mitochondrial membrane potential staining, live-dead staining and scratch assay were used to verify the in vitro photothermal effect of UPS, and the stimulation of UPS on immune-related pathways at the gene level was analyzed by sequencing. Biological safety analysis and pharmacokinetic analysis of UPS were performed. Finally, the amplification effect of UPS-mediated photothermal therapy on aPD-L1-mediated immunotherapy and the corresponding mechanism were studied. Results: In vitro experiments showed that UPS had strong photothermal therapy ability and was able to stimulate 5 immune-related pathways. In vivo, when the PTT assisted aPD-L1 treatment, it exhibited a significant increase in CD4+ T cell infiltration by 14.46-fold and CD8+ T cell infiltration by 14.79-fold, along with elevated secretion of tumor necrosis factor-alpha and interferon-gamma, comparing with alone aPD-L1. This PTT assisted aPD-L1 therapy achieved a significant inhibition of both primary tumors and distant tumors compared to the alone aPD-L1, demonstrating a significant difference. Conclusion: The nanotheranostic agent UPS has been introduced into immunotherapy, which has effectively broadened its application in biomedicine. This photothermal therapeutic approach of the UPS nanotheranostic agent enhancing the efficacy of aPD-L1 immune checkpoint blockade therapy, can be instructive to address the challenges associated with immunotherapy resistance, thereby offering potential for clinical translation.

1 May 2025 in Digital Health
Verified
Journal Article
Open access
ZLZhiyong Lin
Zhiyong Lin
JDJingyi Deng
Jingyi Deng
SCShiming Chen
Shiming Chen
JHJiawen He
Jiawen He
ZLZhiquan Li
Zhiquan Li
TZTianen Zhou
Tianen Zhou
Objective: Sepsis remains a critical global healthcare challenge with high mortality rates, where traditional diagnostics lack sensitivity and standardized treatments show limited efficacy due to patient variability. While artificial intelligence (AI) has advanced sepsis diagnosis and management, systematic bibliometric analyses are scarce, particularly regarding recent research trends from 2022 to 2025. This study aims to reveal research development patterns and frontier dynamics of AI applications in sepsis diagnosis and management, providing strategic guidance and decision support for researchers, clinicians, and policymakers in this rapidly evolving field. Methods: Web of Science data related to AI in sepsis published from 2005 to 2025 were retrieved. Multidimensional bibliometric and visualization analyses were conducted using VOSviewer, CiteSpace, and Bibliometrix packages. Results: AI applications in sepsis research demonstrated exponential growth since 2016, peaking at 352 publications and 1363 citations in 2024. The United States dominates both publication volume (487 papers) and citation impact (12,984 citations), while China ranks second in output (457 papers) but shows significantly lower impact (3929 citations). Research clustered into six major directions encompassing intelligent prediction, molecular mechanisms, and deep learning early warning systems. Post-2022 analysis revealed emerging keywords including “ARDS (Acute Respiratory Distress Syndrome),” “MIMIC-IV,” and “immune infiltration,” signaling shifts toward multi-omics integration and precision medicine. The most highly cited studies focused on sepsis phenotypic subtyping (776 citations) and AI treatment strategies (619 citations). Conclusion: AI applications in sepsis research are transitioning from algorithm validation toward clinical application, developing in the direction of explainable AI and precision sepsis care. The research trajectory evolves from “proof of concept” toward “ensuring clinical utility.” These findings provide strategic guidance for healthcare systems, highlighting the importance of interpretable models, multi-center validation, and infrastructure development for next-generation precision sepsis management.

1 May 2024 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
JHJingmei Huang
Jingmei Huang
LGLianshan Guo
Lianshan Guo
XHXiaoxiao Huang
Xiaoxiao Huang
XYXiaoping Yu
Xiaoping Yu
LLLiqiao Lin
Liqiao Lin
ZLZhengzhao Li
Zhengzhao Li
Purpose: The study aimed to address the non-specific toxicity of cytotoxins (CTX) in liver cancer treatment and explore their combined application with the photosensitizer Ce6, co-loaded into carbonized Zn/Co bimetallic organic frameworks. The goal was to achieve controlled CTX release and synergistic photodynamic therapy, with a focus on evaluating anti-tumor activity against human liver cancer cell lines (Hep G2). Methods: Purified cobra cytotoxin (CTX) and photosensitizer Ce6 were co-loaded into carbonized Zn/Co bimetallic organic frameworks, resulting in RGD-PDA@C-ZIF@(CTX+Ce6). The formulation was designed with surface-functionalization using polydopamine and tumor-penetrating peptide RGD. This approach aimed to facilitate controlled CTX release and enhance the synergistic effect of photodynamic therapy. The accumulation of RGD-PDA@C-ZIF@(CTX+Ce6) at tumor sites was achieved through RGD’s active targeting and the enhanced permeability and retention (EPR) effect. In the acidic tumor microenvironment, the porous structure of the metal-organic framework disintegrated, releasing CTX and Ce6 into tumor cells. Results: Experiments demonstrated that RGD-PDA@C-ZIF@(CTX+Ce6) nanoparticles, combined with near-infrared laser irradiation, exhibited optimal anti-tumor effects against human liver cancer cells. The formulation showcased heightened anti-tumor activity without discernible systemic toxicity. Conclusion: The study underscores the potential of utilizing metal-organic frameworks as an efficient nanoplatform for co-loading cytotoxins and photodynamic therapy in liver cancer treatment. The developed formulation, RGD-PDA@C-ZIF@(CTX+Ce6), offers a promising avenue for advancing the clinical application of cytotoxins in oncology, providing a solid theoretical foundation for future research and development.